A total of 1,007 clinical isolates from a tertiary care center were te
sted against RU 29246, ampicillin, cephalothin, cefoxitin, ceftazidime
, Augmentin, oxacillin, piperacillin, gentamicin, amikacin and vancomy
cin. Bacteria tested consisted of 479 strains of Enterobacteriaceae, 6
4 pseudomonads, 18 Xanthomonas, 42 other gram-negative bacilli, 56 ent
erococci and 348 isolates of staphylococci. RU 29246 showed excellent
in vitro activity inhibiting > 90% of Escherichia coli, Klebsiella pne
umoniae, K. oxytoca, Enterobacter Proteus mirabilis, Providencia, Morg
anella, Salmonella, Shigella, Aeromonas hydrophila, and methicillin-su
sceptible Staphylococcus aureus at an MIC of 0.5-1.0 mg/l. Seventy-sev
en percent coagulase-negative staphylococci had an MIC of 1.0-4.0 mg/l
. All strains of Pseudomonas aeruginosa and X maltophilia were resista
nt to RU 29246. Fifty-six percent of the enterococcal isolates were in
hibited by 1.0-1 6.0 mg/l of RU 29 246.